… encouraging results with generally manageable toxicity in therapeutic trials of patients with
… the use of bortezomib, thalidomide, and lenalidomide as first-generation novel therapies in …

… as proteasome inhibitor bortezomib and Akt inhibitor perifosine (19… in vitro and in vivo cytotoxic
activity in MM cells lines and … LBH589 is a potent antimyeloma agent that overcomes drug …

… of novel agents such as bortezomib and lenalidomide into … enhance the activity of other
anti-myeloma agents. This occurred … I trial, which recommended a perifosine dose of 50 mg daily …

… to other antimyeloma agents, and bortezomib has now been … with CNTO 328, perifosine,
tanespimycin and vorinostat. … ) or lenalidomide and dexamethasone; 103 and groupings with …

… myeloma cells, we treated MM cell lines with different doses … , dexamethasone, lenalidomide,
or bortezomib. As shown in Fig… dexamethasone or bortezomib, but not with other drugs, had …

… lenalidomide overcomes drug resistance in MM cell lines … perifosine for patients with
relapsed or refractory MM, and a phase I/II study of lenalidomide, dexamethasone and bortezomib …

… with existing agents such as dexamethasone, revlimid, and panobinostat and also …
Perifosine induced cytotoxicity in MM cell lines and patient cells and synergized with bortezomib, …

… doses in a bortezomib and lenalidomide refractory population … In vitro studies have suggested
significant antimyeloma activity … Preclinical in vitro studies showed that perifosine induces …

… Summary of known renal toxicities of antimyeloma agents (not … Similar to bortezomib,
carfilzomib has been associated with TMA … Perifosine is an alkylphospholipid that inhibits the Akt …

… Here we review in detail the novel anti-myeloma agent elotuzumab describing … cell line
MM1 with subtoxic doses of dexamethasone, bortezomib, lenalidomide, AKt inhibitor perifosine …